Proteomics Shared Resource

项目摘要：蛋白质组学共享资源(PSR) 蛋白质是生物学的最终执行者，几乎所有的细胞过程都依赖于 由基因的蛋白质产物进行的分子工作。此外，还有巨大的监管潜力。 可以通过可逆的化学翻译后翻译微调蛋白质功能而被敏锐地利用 修饰和与其他蛋白质伙伴的相互作用。由于这些功能，大多数癌症 药物直接作用于蛋白质靶点或对蛋白质功能产生依赖(例如，DNA损伤剂 这压倒了参与修复的蛋白质酶)。在癌症研究中，人们越来越认识到这一点 在不了解蛋白质网络动力学(即蛋白质组动力学)的情况下，基因组和 转录数据往往不足以确定有针对性或“可采取行动”的事件和机制 对治疗的抵抗力。蛋白质组学在癌症研究中的目标是定义复杂和 与癌症的发生和发展相关的动态蛋白质信号网络，并使用 这些信息用于识别新的治疗靶点和生物标记物，可以预测疗效或 对特定疗法的抵抗力。我们已经建立了一个全面的蛋白质生物学共享资源 在癌症生物学和蛋白质生物化学方面有很强的背景。因为没有单一的技术平台可以 分析细胞蛋白质组的方方面面、多重浓缩、纯化和测量方法 都是为了解决DLDCCC调查人员研究的各种研究问题而开发的。具体地说，我们的 共享资源通过定制的RPPA平台和一套 基于质谱学的表达谱分析和蛋白质相互作用的测定。此外， 认识到“大数据”的挑战，我们在数据分析和沟通方面力求卓越。我们的 因此，服务以首尾套餐的形式提供，以协助调查人员进行前期研究设计 并进行可行性评估，由各技术平台进行实验分析，专业化 后续研究中的数据分析和解释、故障排除和决策。

PROJECT SUMMARY: Proteomics Shared Resource (PSR) Proteins are the ultimate executors of biology, with nearly all cellular processes being dependent on the molecular work performed by protein products of genes. Furthermore, there is a tremendous regulatory potential that can be acutely utilized through fine-tuning of protein function through reversible chemical post-translational modifications and interactions with other protein partners. Because of these functionalities, a majority of cancer drugs act directly on protein targets or create a dependency on a protein function (e.g., DNA damage agents that overwhelm protein enzymes involved in repair). It is now an increasing realization in the cancer research field that without knowledge of the dynamics of protein networks (i.e., proteome dynamics), genomic and transcriptomic data are often insufficient for determination of targetable, or “actionable,” events and mechanisms of resistance to treatment. The goal of proteomics in cancer research is to define perturbations of complex and dynamic protein signaling networks that are associated with development and progression of cancer and to use this information for identification of novel therapeutic targets and biomarkers that can predict response or resistance to specific therapies. We have established a comprehensive Shared Resource for protein biology with a strong background in cancer biology and protein biochemistry. Since there is no single technology platform to analyze all aspects of the cellular proteome, multiple enrichment, purification, and measurement approaches have been developed to address diverse research questions studied by DLDCCC investigators. Specifically, our Shared Resource provides targeted antibody-based protein profiling with custom RPPA platform and a suite of mass spectrometry-based assays for expression profiling and determination of protein interactions. Furthermore, recognizing the challenges of “big data,” we strive for excellence in data analysis and communication. Our services are therefore provided as beginning-to-end packages to assist investigators with up-front study design and feasibility assessment, execution of experimental analysis by various technology platforms, specialized analysis and interpretation of data, troubleshooting, and decision-making in follow-up studies.